UBS‘ asset management arm weighs in on the market outlook later in the year
The firm says that they expect some form of emergency approval of between one to three coronavirus vaccines during Q4 2020, adding that they expect „full approval for broad inoculation to begin by the middle of next year“.
The firm says that they expect some form of emergency approval of between one to three coronavirus vaccines during Q4 2020, adding that they expect „full approval for broad inoculation to begin by the middle of next year“.